Long-term follow-up data on the effects of screening are scarce, and debate exists on the relative contribution of screening versus treatment to breast cancer mortality reduction. Our aim was therefore to assess the long-term effect of screening by age and time of implementation. We obtained data on 69,630 breast cancer deaths between 1980 and 2010 by municipality (N 5 431) and age of death (40-79) in the Netherlands. Breast cancer mortality trends were analyzed by defining the municipality-specific calendar year of introduction of screening as Year 0. Additionally, log-linear Poisson regression was used to estimate the turning point in the trend after Year 0, per municipality, and the annual percentage change (APC) before and after this point. Twenty years after introduction of screening breast cancer mortality was reduced by 30% in women aged 55-74 and by 34% in women aged 75-79, compared to Year 0. A similar and significant decrease was present in municipalities that started early (1987)(1988)(1989)(1990)(1991)(1992) and late (1995)(1996)(1997) with screening, despite the difference in availability of effective adjuvant treatment. In the age groups 55-74 and 75-79, the turning point in the trend in breast cancer mortality was estimated in Years 2 and 6 after the introduction of screening, respectively, after which mortality decreased significantly by 1.9% and 2.6% annually. These findings show that the implementation of mammography screening in Dutch municipalities is associated with a significant decline in breast cancer mortality in women aged 55-79, irrespective of time of implementation.
Mammography screening has been shown to reduce breast cancer mortality in various randomized controlled trials. [1] [2] [3] [4] After the outcomes of these trials, population-based screening programmes have been implemented in many European countries. 5 In the Netherlands, mammography screening for women aged 50 to 69 was gradually implemented between 1987 and 1997 and extended to age 74 between 1998 and 2001.
Numerous observational studies have assessed the impact of population-based screening on breast cancer mortality. [6] [7] [8] [9] [10] The International Agency for Research on Cancer (IARC) has recently released a report on breast cancer screening in which the value of these studies was assessed. 11 Based on observational studies that were considered to be "informative for evaluating the effectiveness of mammographic screening programmes," the experts concluded that there is sufficient evidence for the effectiveness of mammography screening in reducing breast cancer mortality in women aged 50 to 69 and 70 to 74. The studies supported an average 23% reduction in breast cancer mortality in 50 to 69-year-old women invited to screening and a reduction of approximately 40% in women who attended screening. 11 Trends in breast cancer mortality rates are often analyzed to estimate the effectiveness of screening programmes. To assess the effect properly, long follow-up after full screening coverage is crucial. However, trend studies with adequate follow-up are scarce. 12 The aim of our study was to assess the effect of population-based screening on breast cancer mortality rates in the Netherlands between 1980 and 2010 using a long follow-up of 20 years after the start of nationwide screening (corresponding to 13 years after full screening coverage was achieved) and approximately 10 years after the extension of screening from age 69 to age 74. By analyzing breast cancer mortality between 1980 and 2010, our study will add 10 years of follow-up to previous work. 6 In addition, the long(er) follow-up after the extension of screening allowed us to assess the full impact of screening between age 50 and 74. Furthermore, breast cancer mortality was analyzed at the municipality level and we could, therefore, account explicitly for the municipality-specific introduction year of screening.
Apart from screening, adjuvant therapy also contributes to a reduction in breast cancer mortality. [13] [14] [15] [16] Adjuvant therapy was introduced in the Netherlands in the early 1980s for women aged 50 years and older 17 and has improved over time. 14 The proportion of breast cancer patients receiving adjuvant therapy in the Netherlands has increased substantially since the early 1980s. [17] [18] [19] [20] It has been argued that more effective therapy will lead to a smaller screening effect. 21 We therefore also compared trends in breast cancer mortality rates in municipalities that started early with screening to trends in late starting municipalities, in which more effective treatment was available.
Methods

Dutch breast cancer screening programme
The breast cancer screening programme for women aged 50-69 in the Netherlands was initiated in 1987-89 in municipalities adjacent to two pilot municipalities (Utrecht and Nijmegen). From 1990 onward, the screening programme was gradually implemented throughout the country, reaching full coverage in 1997. The programme was extended to age 74 between 1998 and 2001. Due to the gradual implementation, there were differences in calendar year of introduction of screening between municipalities. In 2003, a pilot study was conducted in which digital mammography was introduced. The proportion of digital mammography screens steadily increased from 1% in 2003 to 100% in June 2010. Women aged 50-74 years are invited to screening once every 2 years in the Netherlands. Mammograms are read independently by two readers. Initially, 2-view mammography was only performed at first screening with 1-view mammography at subsequent screens. However, 2-view mammography was increasingly performed at subsequent screens over the years, from around 50% of all screens in 2004 to over 90% in 2010.
22, 23 The attendance rate in the Dutch screening programme has been around 80% since the introduction of screening, with only small differences between age groups. 22 The recall rate was 9.9 per 1000 women screened during the introduction of screening, between 1990 and 1997, and increased to 21.4 per 1,000 in 2011.
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Between 1980 and 2010, the number of municipalities decreased from 812 to 431, due to mergers of municipalities. Our dataset included all municipalities and thus consisted of municipalities that remained unchanged between 1980 and 2010, municipalities that were merged, but had the same calendar year of introduction of screening and a small number of municipalities that were merged and had different calendar years of introduction of screening. In the latter group, the linking of breast cancer deaths occurring after the merger of municipalities to the correct calendar year of introduction of screening is not straightforward and is described in the Supporting Information.
Data
Breast cancer deaths between 1980 and 2010 and population data by calendar year, age at death (ages 40-79) and municipality were obtained from Statistics Netherlands. 24 All deaths in the Netherlands are recorded by Statistics Netherlands by cause of death and last known address. The cause of death is assessed by use of the death certificate with the indication of death determined by the attending physician. Based on evidence from the literature, many have argued to expect a delay of 3-5 years after first invitation to screening (age 50) in the full effect of screening on breast cancer mortality. 25 We therefore used the following age groups: 55-74 (referred to as "women invited to screening"); 40-54 ("younger women") and 75-79 ("older women").
Statistical analyses
To correct for the gradual implementation of screening, we transformed calendar years to years relative to the municipality-specific year of introduction of screening, defined as Year 0. Preceding and subsequent years, before and after the introduction of screening, were indicated as years 21, 22, 23, etc. and 1, 2, 3, etc., respectively. Results are thus presented by year since introduction of screening instead of calendar year. Because of the gradual implementation, the maximum follow-up period of a municipality after the introduction of screening ranges from 13 (introduction of screening in 1997) to 23 (introduction of screening in 1987) years. Breast cancer mortality trends were analyzed using loglinear Poisson regression. We calculated breast cancer mortality rates per 100,000 woman-years, using the number of breast cancer deaths as the numerator and the mid-year female population size as the denominator. Age-standardisation 26 was done to allow for (visual) comparability of mortality rates. In addition, we calculated breast cancer mortality rates relative to the rate at time of introduction of screening
What's new?
What's the public health impact of cancer screening over the long term? Not much data has been collected to quantitatively answer that. To find out, these authors collected data on breast cancer mortality in the Netherlands over a period of 20 years after the introduction of a national screening program. They observed a 30% decrease in breast cancer mortality among women age 55-74 after screening commenced. Similarly, in older women, age 75-79, mortality decreased by 34%.
in women invited to screening (55-74), for each year before and after the introduction of screening, by using the breast cancer mortality rate in Year 0 as a reference value (value 1 in the graph). The relative breast cancer mortality rate in a given year thus reflects the proportion of breast cancer mortality compared to the breast cancer mortality rate in Year 0, in which screening was introduced. Corresponding 95% confidence intervals (CIs) were also calculated.
We performed an additional analysis by using log-linear Poisson regression (on the number of breast cancer deaths and woman-years) to assess the best estimate for a knot (referred to as "turning point") in the trend in breast cancer mortality after the introduction of screening (Year 0), using the municipality-specific calendar year of introduction of screening. This turning point reflects the most probable year in which the mortality trend changes after the introduction of screening. Slopes before and after the turning point were estimated to calculate the annual percentage change (APC) and the corresponding 95% CI. The methods and results of this analysis are extensively described in the Supporting Information. All analyses were performed using R 3.0.2. 
Results
Our dataset consisted of 431 municipalities in 2010 and 69,630 breast cancer deaths between 1980 and 2010 ( Table  1 ). The distribution of breast cancer deaths among age groups and early, intermediate and late starters is also shown in Table 1 . The age-standardized breast cancer mortality rates by age group relative to the year in which screening was introduced at the municipality level (Year 0) are displayed in Figure 1 . In women invited to screening (55-74), there is a slight increase in breast cancer mortality before the introduction of screening at the municipality level followed by a strong decrease afterward. A similar decline is visible for women aged 75-79, a few years later (women aged 70-74 were on average invited to screening 5 years later than women aged 50-69). In women aged 40-54, the mortality rate starts to decline moderately a few years before the introduction of screening (Fig. 1) . The underlying rates per year relative to 
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the introduction of screening are listed in the Supporting Information (Tables 1a and 1b) . The relative breast cancer mortality rates for women aged 55-74 show a reduction in breast cancer mortality 20 years after the introduction of screening of 30% (Fig. 2) . In the age group 75-79, there was a significant 34% reduction in Year 20, compared to Year 0 (Fig. 1) .
The turning point in the breast cancer mortality trend was estimated in Year 2 after the introduction of screening in women aged 55-74 years and in Year 6 after introduction in women aged 75-79 years, with corresponding significant annual decreases of 1.9% and 2.6%, respectively, from these points onward (Supporting Information, Table 2 ]).
Early, intermediate and late starters
The age-standardized mortality rates, for women invited to screening (age group 55-74), are similar for early, intermediate and late starters before and after the introduction of screening. All three groups show a strong and similar decline in breast cancer mortality related to the introduction of screening at the municipality level, despite the (expected) difference in therapy regimens (Fig. 3) .
The trend in breast cancer mortality was estimated to change from a stable to a significantly declining rate in Year 2 (early starters; 1987-1992) and Year 4 (intermediate and late starters; 1993-1994 and 1995-1997) after the introduction of screening. After the turning point the mortality rates in the three groups declined significantly between 2.2% and 2.9% per year (Supporting Information, Table 2 ).
Discussion
Our results show a strong change in breast cancer mortality trends in women aged 55-74 and 75-79, related to the municipality-specific introduction of screening in the age groups 50-69 and 70-74. The results support that mammography screening from age 50 to 74 contributes to a reduction in breast cancer mortality. The decline in breast cancer mortality in women aged 55-74 was estimated to be 30% after 20 years of follow-up since the introduction of screening. For these women we estimated a significant annual decline of 1.9% over 11-21 years of follow-up, from Year 2 after the introduction of screening onward. Breast cancer mortality in older women (75-79) was reduced by 34% after 20 years of follow-up and was estimated to decrease significantly by 2.6% annually over 7-17 years of follow-up, from Year 6 after the introduction of screening onward.
The observed start of the decline in breast cancer mortality (and the estimated turning point in Year 2) might seem early and in conflict with the expectation that the full effect of screening cannot be observed before 3-5 years after the first invitation to screening (we only accounted for a time delay in age, not for a delay in calendar time). However, the estimate of the delay in the effect of screening is largely based on results of the randomized controlled trials of breast cancer screening, which started in the early 1980s. As the number of breast cancer deaths in our study is substantially higher than in any of the trials, which had around 750-2,000 breast cancer deaths, 1, 27, 28 it is plausible that the effect of screening already occurs before 3 years after its introduction. Also, at the time of introduction of screening, there may have been women with metastasized breast cancer who were not yet diagnosed and who would have died within 2 years in the absence of screening. Screen-detection may have averted death in some of these cases, which could have led to a rapid effect on breast cancer mortality rates in terms of mortality reduction. More importantly, a change in the trend in breast cancer mortality, from a stable to a downward trend, after the introduction of screening is likely to occur before the point in time at which the full effect of screening can be observed.
A major strength of our study is the long period of follow-up of >10 years, both after full coverage of the screening programme was achieved in 1997 and from the extension of screening from age 69 to age 74 in 1998. Another strength is that we had nationwide coverage, as we obtained mortality data of all 431 municipalities in the Netherlands in 2010, and 69,630 breast cancer deaths. Trend analyses of population mortality rates over time are often considered to have drawbacks with respect to the quantification of the effect of screening. 12 Our study was carefully designed to account for some of these drawbacks. We accounted for differences in calendar year of introduction of screening between municipalities by analyzing our data by year relative to introduction of screening at the municipality level rather than by calendar year. An observed effect of screening may be diluted by breast cancer deaths in women diagnosed with breast cancer before screening was introduced (prevalent tumors). This may, however, not be a major issue in our analysis as we assessed breast cancer mortality in the age group 55-74 (rather than 50-74) and we calculated the annual percentage change in breast cancer mortality rates after the estimated turning point (rather than directly after the introduction of screening). These aspects of study design have been argued to limit the bias resulting from inclusion of death from prevalent tumors. 12 Nevertheless, there will be some dilution of the screening effect in the first years after the introduction of screening. However, it is plausible that the turning point in the trend occurs before the full effect of screening can be observed, even if there is dilution in the early years after the introduction of screening.
Our study had some limitations. As women who participated in screening, at the time it was introduced, in a certain municipality may have moved to another municipality afterward, the correlation between the municipality-specific introduction year of screening and female inhabitants will become smaller over time. In addition, a study based on individual data would have been more accurate and reliable. However, this was not possible due to privacy legislation. Furthermore, in the Netherlands participation is relatively high (on average 80% in each screening round), 22 but, because we had no individual data on screening participation, the screening effect is diluted by non-participation. Finally, the comparisons between the trends in the age group invited to screening (55-74) and younger women (40-54) should be considered with caution as the administration of adjuvant treatment before and after the introduction of screening differed between these age groups in the Netherlands. 17 After introduction of screening, we observed a 30% reduction in breast cancer mortality in women invited to screening which is consistent with reduction estimates in the age group invited to population-based screening from other studies 29, 30 and in agreement with the 25% reduction shown by the randomized trials of mammography screening. 25 Our results are in line with trend studies, with adequate follow-up after complete coverage of screening, which demonstrate a strong association between the introduction of mammography screening and breast cancer mortality reduction. 8, 29 Furthermore, we estimated an annual decline in breast cancer mortality of 1.9% from Year 2 after the introduction of screening onward in women aged 55-74, which corresponds to the previously reported 1.7% annual decline, after the introduction of screening in the Netherlands. 6 Our estimate is also within the range of reductions of 1-9% per year, reported by earlier European trend studies. 12, 31 The effect of the extension of the upper age limit of screening to age 74 between 1998 and 2001 on breast cancer mortality in women aged 75 and older was not (yet) reflected in the results of earlier research, 6 because of limited followup after this extension. Women aged 70-74 were, on average, invited 5 years later to screening than women aged 50-69.
Having long-term follow-up data now, our results support a downturn in breast cancer mortality for women aged 75-79, showing a steep decline in this age group. The size of the change in the breast cancer mortality trend, after the introduction of screening, observed in our study was larger in the oldest age group (75-79) than in younger women aged 55-74 (APC of 2.6 vs APC of 1.9), which is in line with earlier findings. 10, 32 The decline in breast cancer mortality in this group reflects a long-term accumulation of screening between ages 50 and 69 and screening between ages 70 and 74. Also, the benefit of screening, in terms of breast cancer mortality reduction, has been shown to increase with the number of screens attended. 33, 34 In addition, as older women tend to have slower tumor growth rates and less dense breasts, [35] [36] [37] test sensitivity of mammography is higher at older age. [38] [39] [40] In women aged 40-54, breast cancer mortality rates started to decline moderately a few years before the introduction of screening. The most probable cause for this downturn is the increasing use of adjuvant therapy, which younger women received significantly earlier than women in the age group 55-74 in the Netherlands. 22 Before the introduction of adjuvant therapy in the 1980s for postmenopausal women (above the age of 55 years), premenopausal node-positive women (under age 55 years) already had received adjuvant chemotherapy for 10 years. 17, 18 Moreover, the proportion of node-positive patients under age 55 years that received adjuvant chemotherapy increased substantially before and around the introduction of screening in the Netherlands. 17 Opportunistic screening (for high-risk women) outside the screening programme may also lower breast cancer mortality. 41 As we expected beforehand, we did not find a turning point related to screening for the age group 40-54 (Supporting Information) as only a small part of this group is invited to screening (i.e., 50-54) and even in this subgroup the full effect of screening may not be observable yet. The effect of adjuvant treatment on breast cancer mortality is clearly also intertwined in the trend in women aged 55-74. A recent modeling study predicted that adjuvant treatment caused a 13.9% reduction in breast cancer mortality in the total Dutch population in 2008, compared to a setting without adjuvant treatment. 16 Simulation of biennial screening from 50 to 74 resulted in an additional 15.7% reduction in breast cancer mortality. Similar contributions of adjuvant treatment and screening to the observed breast cancer mortality reduction were also predicted by an earlier modeling study from the United States. 42 
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It is difficult to disentangle the effect of screening and treatment after the introduction of screening. Adjuvant endocrine therapy (Tamoxifen) was introduced in the 1980s in the Netherlands, before the introduction of screening, for postmenopausal patients with node-positive and estrogen receptor (ER) positive breast cancer. 17 Over the years, adjuvant treatment has improved and its usage has increased significantly. 14, [17] [18] [19] [20] For example, from 1998 onward, nodenegative patients also received adjuvant systemic therapy, which is likely to have contributed to the decline in breast cancer mortality afterward. Our results show that breast cancer mortality did not decrease before the introduction of screening in women invited to screening and older women, despite these improvements in therapy, which is in line with previous work. 8, 32 We did not observe differences in breast cancer mortality rates between municipalities in which screening was introduced rather early and municipalities in which screening was introduced rather late, with the latter having more effective adjuvant treatment available in the years before and after the introduction of screening. More importantly, a strong significant decline in breast cancer mortality shortly after the introduction of screening was present in both early, intermediate and late starters, suggesting a crucial role for screening in this downturn, irrespective of the quality and the extent of treatment. The annual decline after the turning point is stronger in late starters (2.9%) than in early starters (2.2%), which may indicate a synergistic effect between early detection and improved adjuvant treatment.
In conclusion, our results show a significant decrease in breast cancer mortality shortly after the introduction of screening at the municipality level in women invited to screening and in older women, similar in early starting municipalities and late starting municipalities (with more effective adjuvant treatment available), indicating that this decrease is strongly associated with the implementation of the national screening programme.
